Antimicrobial Resistance and Epidemiological Study of Clinically Relevant Pathogens

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 875

Special Issue Editors


E-Mail Website
Guest Editor
Department of Microbiology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
Interests: antimicrobials; antibiotic resistance; microbiology; healthcare associated infections; COVID-19; SARS-CoV-2
Special Issues, Collections and Topics in MDPI journals
Department of Microbiology, “George Emil Palade” University of Medicine, Pharmacy, Sciences and Technology, Targu Mures, Romania
Interests: bacteriology; molecular biology; mycology; virology; antimicrobial activity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Microbiology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
Interests: antibacterial resistance; hospital-acquired infections; new antimicrobial compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The escalating threat of bacterial resistance poses a significant challenge in contemporary healthcare, leading to critical clinical implications that profoundly impact treatment options. In recent years, infections caused by multidrug-resistant organisms (MDROs) have become endemic in numerous healthcare facilities, resulting in hospital-acquired outbreaks reported globally. Several factors contribute to the varying prevalence of MDRO acquisition across departments, including individual patient risk factors such as underlying diseases, recent hospital admissions, the presence of vascular catheters, major surgeries, and recent antibiotic therapies.

Local factors further influence MDRO acquisition, such as excessive bed occupancy, inadequate patient isolation rooms, high patient-to-nurse ratios, and suboptimal compliance with standard precautions, including hand hygiene and environmental decontamination. There is a growing interest in understanding the role of the environment in patient MDRO acquisition, shedding light on bacterial adaptability, exemplified by the production of bacterial biofilm to facilitate adherence.

Advances in genotyping methods, particularly whole genome sequencing, offer exciting opportunities to trace the spread of microorganisms either between patients or from the environment to a patient. In this context, we invite contributions for our Special Issue, with a focus on, but not limited to, the following topics:

  • The molecular characterization of multidrug-resistant bacteria;
  • Correlation between antibiotic use and resistance patterns;
  • The identification of risk factors for acquired multidrug resistance;
  • The evaluation of local trends in multidrug-resistant bacteria;
  • The investigation of novel methods for rapid resistance detection;
  • The assessment of antimicrobial activity of new compounds;
  • The relationship between the environment and resistant pathogens.

We encourage submissions of both original research and review articles. Your valuable contributions will significantly advance our understanding of bacterial multidrug resistance and antimicrobial activity.

Dr. Florin George Horhat
Dr. Adrian Man
Dr. Delia Muntean
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibacterial activity
  • antimicrobial resistance
  • infections
  • multidrug-resistant pathogens
  • virulence gene expression
  • drug discovery
  • epidemiological study

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 3859 KiB  
Article
Prevalence of Infections and Antimicrobial Resistance of ESKAPE Group Bacteria Isolated from Patients Admitted to the Intensive Care Unit of a County Emergency Hospital in Romania
by Alina-Simona Bereanu, Rareș Bereanu, Cosmin Mohor, Bogdan Ioan Vintilă, Ioana Roxana Codru, Ciprian Olteanu and Mihai Sava
Antibiotics 2024, 13(5), 400; https://doi.org/10.3390/antibiotics13050400 (registering DOI) - 27 Apr 2024
Viewed by 127
Abstract
The ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella Pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) is a group of bacteria very difficult to treat due to their high ability to acquire resistance to antibiotics and are the [...] Read more.
The ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella Pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) is a group of bacteria very difficult to treat due to their high ability to acquire resistance to antibiotics and are the main cause of nosocomial infections worldwide, posing a threat to global public health. Nosocomial infections with MDR bacteria are found mainly in Intensive Care Units, due to the multitude of maneuvers and invasive medical devices used, the prolonged antibiotic treatments, the serious general condition of these critical patients, and the prolonged duration of hospitalization. Materials and Methods: During a period of one year, from January 2023 to December 2023, this cross-sectional study was conducted on patients diagnosed with sepsis admitted to the Intensive Care Unit of the Sibiu County Emergency Clinical Hospital. Samples taken were tracheal aspirate, catheter tip, pharyngeal exudate, wound secretion, urine culture, blood culture, and peritoneal fluid. Results: The most common bacteria isolated from patients admitted to our Intensive Care Unit was Klebsiella pneumoniae, followed by Acinetobacter baumanii and Pseudomonas aeruginosa. Gram-positive cocci (Enterococcus faecium and Staphilococcus aureus) were rarely isolated. Most of the bacteria isolated were MDR bacteria. Conclusions: The rise of antibiotic and antimicrobial resistance among strains in the nosocomial environment and especially in Intensive Care Units raises serious concerns about limited treatment options. Full article
Show Figures

Figure 1

29 pages, 3565 KiB  
Article
Inhibition of Clinical MRSA Isolates by Coagulase Negative Staphylococci of Human Origin
by Ellen Twomey, Paula M. O’Connor, Aidan Coffey, Maija Kiste, Caitriona M. Guinane, Colin Hill, Des Field and Máire Begley
Antibiotics 2024, 13(4), 338; https://doi.org/10.3390/antibiotics13040338 - 08 Apr 2024
Viewed by 508
Abstract
Staphylococcus aureus is frequently highlighted as a priority for novel drug research due to its pathogenicity and ability to develop antibiotic resistance. Coagulase-negative staphylococci (CoNS) are resident flora of the skin and nares. Previous studies have confirmed their ability to kill and prevent [...] Read more.
Staphylococcus aureus is frequently highlighted as a priority for novel drug research due to its pathogenicity and ability to develop antibiotic resistance. Coagulase-negative staphylococci (CoNS) are resident flora of the skin and nares. Previous studies have confirmed their ability to kill and prevent colonization by S. aureus through the production of bioactive substances. This study screened a bank of 37 CoNS for their ability to inhibit the growth of methicillin-resistant S. aureus (MRSA). Deferred antagonism assays, growth curves, and antibiofilm testing performed with the cell-free supernatant derived from overnight CoNS cultures indicated antimicrobial and antibiofilm effects against MRSA indicators. Whole genome sequencing and BAGEL4 analysis of 11 CoNS isolates shortlisted for the inhibitory effects they displayed against MRSA led to the identification of two strains possessing complete putative bacteriocin operons. The operons were predicted to encode a nukacin variant and a novel epilancin variant. From this point, strains Staphylococcus hominis C14 and Staphylococcus epidermidis C33 became the focus of the investigation. Through HPLC, a peptide identical to previously characterized nukacin KQU-131 and a novel epilancin variant were isolated from cultures of C14 and C33, respectively. Mass spectrometry confirmed the presence of each peptide in the active fractions. Spot-on-lawn assays demonstrated both bacteriocins could inhibit the growth of an MRSA indicator. The identification of natural products with clinically relevant activity is important in today’s climate of escalating antimicrobial resistance and a depleting antibiotic pipeline. These findings also highlight the prospective role CoNS may play as a source of bioactive substances with activity against critical pathogens. Full article
Show Figures

Figure 1

Back to TopTop